New insights in the management of elderly patients with acute myeloid leukemia

Current Opinion in Oncology

Volumn 21, Issue 6, 2009, Pages 589-593

  Dombret, Hervé ^a   Raffoux, Emmanuel ^a   Gardin, Claude ^b  

^a SAINT LOUIS HOSPITAL   (France)

^b UNIVERSITÉ PARIS 13   (France)

Author keywords

Acute myeloid leukemia; Elderly, prognosis; Treatment decision making

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANDROGEN; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; AZACITIDINE; CLOFARABINE; CYTARABINE; DAUNORUBICIN; IDARUBICIN; RETINOIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ANDROGEN THERAPY; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; ELDERLY CARE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INTENSIVE CARE; LOW DRUG DOSE; MEDICAL DECISION MAKING; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; REDUCED INTENSITY CONDITIONING; REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ACUTE DISEASE; MYELOID LEUKEMIA; OUTCOME ASSESSMENT; REMISSION;

ACUTE DISEASE; AGED; HEALTH SERVICES FOR THE AGED; HUMANS; LEUKEMIA, MYELOID; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; REMISSION INDUCTION;

EID: 74049093159     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3283313e10     Document Type: Review

References (28)

1. Sekeres MA, Stone RM, Zarieh D, et al. Decision-making and quality of life In older patients with acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia 2004; 18:809-816.
2. Menzin J, Lang K, Earle CC, et al. The outcome and costs of acute myeloid leukemia In the elderly. Arch Intern Med 2002; 162:1597-1603. (Pubitemid 34773427)
3. Derolf AR, Krlstinsson SY, Andersson TML, et al. Improved patient survival for acute myeloid leukemia: a population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005. Blood 2009; 113:3666-3672.
4. Jullusson G, Antunovio P, Derolf A, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009; 113:4179-4187.
5. Schuler US, Hanel M, Bodenstein H, et al. Evaluation of clinical judgment atinitiation of AML-therapy In elderly patients: a prospective randomized study.Blood (2007 ASH Annual Meeting Abstracts); 110: abstract 2863.
6. Kantarjlan H, O'Brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome. Cancer 2006; 106:1090-1098.
7. Wheatley K, Brookes CL, Howman AJ, et al. Prognostic factor analysis of the survival of elderly patients with AML In the MRC AML11 and LRF AML14 trials. Br J Haematol 2009; 145:598-605.
8. Malfuson JV, Etienne A, Turlure P, et al. Risk factors and decision criteria for intensive chemotherapy In older patients with acute myeloid leukemia. Haematologica 2008; 93:1806-1813.
9. Sekeres MA, Elson P, Kalaycio ME, et al. Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients. Blood 2009; 113:28-36.
10. Sorror ML, Marris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-speolfic co-morbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106:2912-2919. (Pubitemid 41510773)
11. Giles FJ, Borthakur G, Ravandi F, et al. The haematopoietic cell transplantation comorbidity Index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol 2007; 136:624-627. (Pubitemid 46148199)
12. Etienne A, Estern B, Charbonnier A, et al. Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia. Cancer 2007; 09:1376-1383. (Pubitemid 46466565)
13. Prebet T, Boissel N, Reutenauer S, et al. Acute myeloid leukemia with translocation (8;21) or inversion (16) In elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup.J Clin Oncol 2009 [Epub ahead of print]
14. Mrázek K, Marcucci G, Paschka P, Bloomfield CD. Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia. Curr Opin Onool 2008;20:711-718.
15. Sohlenk RF, Döhner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358:1909-1918. (Pubitemid 351620111)
16. Becker H, Marcucci G, Maharry K, et al. NPM1 mutations as an Independent prognosticator for older cytogenetically normal acute myeloid leukemia (CN AML) J Clin Oncol (2009 ASCO Meeting Abstracts); 27: abstract 7000.
17. Schlenk RF, Donner K, Kneba M, et al. Gene mutations and response to treatment with all-trans retlnoic acid In elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B. Haematologica 2009; 94:54-60.
18. Fernandez H, Sun Z, Yao X, et al. Anthraoycline dose Intensification In acute myeloid leukemia. N Engl J Med 2009;361:1249-1259.
19. Löwenberg B, Ossenkoppele GJ, van Putten W, et al. Daunorlbicin for acute myeloid leukemia In patients over sixty. N Engl J Med 2009; 361:1235-1248.
20. Pautas C, Merabet F, Thomas X, et al. A randomized study of intensified anthraoycilne doses for induction and recombinant interleuklne-2 for maintenance In patients with acute myeloid leukemia aged 50 to 70 years old.Results of the Acute Leukemia French Association (ALFA) 9801 Study. J Clin Oncol 2009 [Epub ahead of print]
21. Dombret H, Gardin C, Chevret S, et al. Long-term survival analysis In older patients with AML treated Intensively: positive impact of idarubicln in a cure fraction estimation model. Blood (2008 ASH Annual Meeting Abstracts); 112: abstract 960.
22. Gardin C, Turlure P, Fagot T, et al. Postremlssion treatment of elderly patients with acute myeloid leukemia In first complete remission after intensive induction chemotherapy: results of the multioenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood 2007; 109:5129-5135. (Pubitemid 46900774)
23. Itzikson R, Gardin C, Pautas C, et al. Impact of post-remission treatments In patients aged 65-70 years with de novo AML: a comparison of two concomitant randomized ALFA trials with overlapping age inciusion criteria. Blood (2008 ASH Annual Meeting Abstracts); 112: abstract 557.
24. Al-Ali H, Cross M, Lange T, et al. Low-dose total body irradiation-based regimens as a preparative regimen for allogeneic haematopoietic cell transplantation in acute myelogenous leukaemia. Curr Opin Oncol 2009; 21 (Suppl 1):S17-S22.
25. Plgneux A, Himberlin C, Hunault-Berger M, et al. Improved outcome with androgens as maintenance treatment in elderly patients with acute myeloid leukemia after ICL regimen as induction therapy: results of the GOELAMS SA-2002 multioenter Phase III randomized open trial. Blood (2008 ASH Annual Meeting Abstracts); 112: abstract 556.
26. Burnett AK, Mllligan D, Prentice AG, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastlc syndrome In patients not considered fit for Intensive treatment. Cancer 2007; 109:1114-1124.
27. Erba HP, Kantarjian HM, Claxton DF, et al. Updated remission duration and survival results of single-agent clofarabine In previously untreated older adult patients with acute myelogenous leukemia (AML) unlikely to benefit from standard Induction chemotherapy due to unfavorable baseline risk factor(s).J Clin Onool (2009 ASCO Meeting Abstracts); 27: abstract 7062.
28. Raffoux E, de Labarthe A, Cras A, et al. Eplgenetic therapy with 5-azacitldine, valproic acid, and ATRA in patients with high-risk acute myeloid leukemia or myelodysplastlc syndrome: results of the French VIVEDEP Phase II study. Blood. (2009 ASH Annual Meeting Abstracts); 112: abstract 763.